Primary outcome
What LIPT measured first
| Liraglutiden=48 | Placebon=24 |
|---|---|
| -56.7(-132.3 to 17.2) | -8.2(-98.7 to 82.3) |
Phase 4 · Liraglutide
LIPT trial results
A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.
Change in Endogenous Thrombin Potential (ETP) (nMolar x minutes), at time 0 and 26 weeks. Liraglutide: -56.7; Placebo: -8.2.
- Participants
- 72
- Status
- completed
- Completed
- 2015-12
- Sponsor
- Jens Faber
As posted on ClinicalTrials.gov (NCT02073929), updated at source Feb 28, 2019. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
Side effects by arm
Side effects in LIPT
Percent of participants affected. The most common events the registry lists.
| Event | Active | Placebo |
|---|---|---|
| Any serious event | 4.2% | 4.2% |
| nausea | 77.1% | 12.5% |
| constipation | 25% | 0% |
| vomiting | 10.4% | 0% |
| diarrhea | 10.4% | 4.2% |
| hypotension | 2.1% | 0% |
Secondary outcomes
What else it measured
| Liraglutiden=48 | Placebon=24 |
|---|---|
| -12(-23 to 0) | 4(-14 to 26) |
The trial
How LIPT was run
Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease. The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS. 70 women will be included in af RCT. Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.
- Active: Liraglutide s.c. 1,8mg daily for 26 weeks
- Placebo: Placebo s.c. daily for 26 weeks
Who could join the trial
Inclusion Criteria: * PCOS * \>18 years * premenopausal * BMI \>25 og 25 and thereunder + insulin resistent Exclusion Criteria (including): * actualt or intended pregnancy * inadeqvat contraception * hormonal contraception within 6 weeks * metfoomin, GLP-1-analog or DPP IV inhibitor within 3 months * medications affectiv hemostatic mechanisme * diabetes or other severe comorbidity * familar MEN * ...
Published papers
Papers from LIPT
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.